Hikma Pharmaceuticals PLC CEO Net Worth

Last Updated Mar 10, 2025
CEO NameRiad Mishlawi
NationalityJordan
Net Worth Estimation$10 million

Riad Mishlawi's estimated net worth of around $10 million primarily derives from his executive compensation and long-term incentive plans at Hikma Pharmaceuticals PLC, including salary, bonuses, and vested company shares. His leadership roles in pharmaceutical operations and corporate strategy have also enhanced his financial standing through performance-based rewards and equity holdings.

Riad Mishlawi, CEO of Hikma Pharmaceuticals PLC, has an estimated net worth of $10,000,000, which is at the minimum end of the $10,000,000 to $90,000,000 range for healthcare CEOs. His net worth represents approximately 11.1% of the maximum estimated CEO net worth in this category.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Riad Mishlawi Performance in Hikma Pharmaceuticals PLC

Riad Mishlawi, CEO of Hikma Pharmaceuticals PLC, demonstrates strategic leadership and data-driven decision-making that drives innovation and operational excellence. Under his guidance, Hikma has improved financial performance and strengthened its global market position through targeted investments and expansion initiatives. His leadership has resulted in enhanced shareholder value and sustained company growth in the competitive pharmaceutical industry.


Latest News

Hikma Pharmaceuticals: Growth Strategy and CEO Riad Mishlawi's Leadership

Hikma Pharmaceuticals, under CEO Riad Mishlawi, has reported strong revenue growth and strategic progress in 2024 and the first half of 2025, with expanded US investments and successful product launches supporting its growth. Mishlawi emphasized the company's focus on manufacturing capabilities, R&D investment, and market expansion, reaffirming a positive outlook for sustained business momentum.
Source: http://www.hikma.com/news/hikma-delivers-a-solid-h1-performance-and-re-affirms-expectations-for-strong-growth-in-the-second-half/



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Hikma Pharmaceuticals PLC are subject to change from time to time.

Comments

No comment yet